These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
137 related articles for article (PubMed ID: 16193890)
1. Acute axonal damage predicts clinical outcome in patients with multiple sclerosis. Lim ET; Sellebjerg F; Jensen CV; Altmann DR; Grant D; Keir G; Thompson EJ; Giovannoni G Mult Scler; 2005 Oct; 11(5):532-6. PubMed ID: 16193890 [TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid levels of brain specific proteins in optic neuritis. Lim ET; Grant D; Pashenkov M; Keir G; Thompson EJ; Söderström M; Giovannoni G Mult Scler; 2004 Jun; 10(3):261-5. PubMed ID: 15222688 [TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid brain specific proteins in relation to nitric oxide metabolites during relapse of multiple sclerosis. Rejdak K; Petzold A; Stelmasiak Z; Giovannoni G Mult Scler; 2008 Jan; 14(1):59-66. PubMed ID: 17893112 [TBL] [Abstract][Full Text] [Related]
4. Axonal damage accumulates in the progressive phase of multiple sclerosis: three year follow up study. Petzold A; Eikelenboom MJ; Keir G; Grant D; Lazeron RH; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G J Neurol Neurosurg Psychiatry; 2005 Feb; 76(2):206-11. PubMed ID: 15654034 [TBL] [Abstract][Full Text] [Related]
5. Neurofilament light and heavy subunits compared as therapeutic biomarkers in multiple sclerosis. Kuhle J; Malmeström C; Axelsson M; Plattner K; Yaldizli O; Derfuss T; Giovannoni G; Kappos L; Lycke J Acta Neurol Scand; 2013 Dec; 128(6):e33-6. PubMed ID: 23763388 [TBL] [Abstract][Full Text] [Related]
6. The new global multiple sclerosis severity score (MSSS) correlates with axonal but not glial biomarkers. Petzold A; Eikelenboom MI; Keir G; Polman CH; Uitdehaag BM; Thompson EJ; Giovannoni G Mult Scler; 2006 Jun; 12(3):325-8. PubMed ID: 16764346 [TBL] [Abstract][Full Text] [Related]
7. Cerebrospinal fluid levels of chitinase 3-like 1 and neurofilament light chain predict multiple sclerosis development and disability after optic neuritis. Modvig S; Degn M; Roed H; Sørensen TL; Larsson HB; Langkilde AR; Frederiksen JL; Sellebjerg F Mult Scler; 2015 Dec; 21(14):1761-70. PubMed ID: 25698172 [TBL] [Abstract][Full Text] [Related]
8. A comparative study of CSF neurofilament light and heavy chain protein in MS. Kuhle J; Plattner K; Bestwick JP; Lindberg RL; Ramagopalan SV; Norgren N; Nissim A; Malaspina A; Leppert D; Giovannoni G; Kappos L Mult Scler; 2013 Oct; 19(12):1597-603. PubMed ID: 23529999 [TBL] [Abstract][Full Text] [Related]
9. Effects of repeated intrathecal triamcinolone-acetonide application on cerebrospinal fluid biomarkers of axonal damage and glial activity in multiple sclerosis patients. Rommer PS; Kamin F; Petzold A; Tumani H; Abu-Mugheisib M; Koehler W; Hoffmann F; Winkelmann A; Benecke R; Zettl UK Mol Diagn Ther; 2014 Dec; 18(6):631-7. PubMed ID: 24986188 [TBL] [Abstract][Full Text] [Related]
10. Gadolinium-enhanced magnetic resonance imaging predicts response to methylprednisolone in multiple sclerosis. Sellebjerg F; Jensen CV; Larsson HB; Frederiksen JL Mult Scler; 2003 Feb; 9(1):102-7. PubMed ID: 12617276 [TBL] [Abstract][Full Text] [Related]
12. Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression. Gnanapavan S; Grant D; Morant S; Furby J; Hayton T; Teunissen CE; Leoni V; Marta M; Brenner R; Palace J; Miller DH; Kapoor R; Giovannoni G PLoS One; 2013; 8(8):e70019. PubMed ID: 23936370 [TBL] [Abstract][Full Text] [Related]
13. Combination of CSF N-acetylaspartate and neurofilaments in multiple sclerosis. Teunissen CE; Iacobaeus E; Khademi M; Brundin L; Norgren N; Koel-Simmelink MJ; Schepens M; Bouwman F; Twaalfhoven HA; Blom HJ; Jakobs C; Dijkstra CD Neurology; 2009 Apr; 72(15):1322-9. PubMed ID: 19365053 [TBL] [Abstract][Full Text] [Related]